AstraZeneca PLC (AZN.L)
| Previous close | 12,096.00 |
| Open | 12,150.00 |
| Bid | 12,280.00 x 0 |
| Ask | 12,284.00 x 0 |
| Day's range | 12,066.00 - 12,286.00 |
| 52-week range | 9,461.00 - 12,488.00 |
| Volume | |
| Avg. volume | 2,800,276 |
| Market cap | 190.307B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 38.48 |
| EPS (TTM) | 3.19 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 2.28 (1.88%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 129.27 |
Yahoo Finance UKTrending tickers: Trump Media, Palo Alto, AstraZeneca and Kingfisher
The latest investor updates on stocks that are trending on Tuesday.
ReutersAstraZeneca aims for $80 billion in total revenue by 2030
AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its cancer, biopharmaceuticals and rare disease portfolio. The Anglo-Swedish drugmaker had reported total revenue of $45.81 billion last year and earlier expected to launch at least 15 new medicines between 2023 and 2030. CEO Pascal Soriot has turned around the company's fortunes since taking over the reins more than a decade ago, rebuilding its new drug pipeline with blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes.
Business WireAstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
CAMBRIDGE, England, May 21, 2024--Investor Day 2024
